Melanoma News and Research

Latest Melanoma News and Research

Data from Provectus' PV-10 pre-clinical study on melanoma to be presented at AACR meeting

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that data on PV-10 will be presented in a poster presentation at the American Association for Cancer Research Annual Meeting in Washington, DC.

23 Jan 2013

STA announces results from ABRAXANE plus gemcitabine phase III trial on pancreatic cancer

Australian biopharmaceutical company Specialised Therapeutics Australia announces that a phase III clinical trial of world leading breast cancer drug ABRAXANE (nanoparticle albumin-bound paclitaxel) in combination with current standard of care gemcitabine in patients with advanced pancreatic cancer has demonstrated substantially improved survival times, with double the number of patients surviving two years.

23 Jan 2013

Incidence of melanoma continues to rise in both men and women: ACS

The American Cancer Society's 2013 Cancer Statistics report found that the incidence of melanoma continues to rise in both men and women. This is particularly concerning because skin cancer can often be easily prevented and detected.

19 Jan 2013

Report: Cancer death rates decline 20% from its peak in 1991

As of 2009, the overall death rate for cancer in the United States had declined 20 percent from its peak in 1991, translating to the avoidance of approximately 1.2 million deaths from cancer, 152,900 of these in 2009 alone. These figures come from the American Cancer Society's annual Cancer Statistics report, one of the most widely-cited medical publications in the world.

17 Jan 2013

SF3B1 gene mutations in uveal melanoma linked to favorable features

Melanomas that develop in the eye often are fatal. Now, scientists at Washington University School of Medicine in St. Louis report they have identified a mutated gene in melanoma tumors of the eye that appears to predict a good outcome.

17 Jan 2013

Iris nevi have ‘low’ malignant potential

The malignant transformation rate for iris nevi is 8% over 15 years, a case series by US researchers has found.

15 Jan 2013

Aggressive surveillance questionable for eye melanoma recurrence

Patients treated for primary choroidal or ciliary body melanoma may not always benefit from an aggressive surveillance strategy for the detection of metastatic disease, caution US researchers.

14 Jan 2013

Intermittent therapy may be answer to treating drug-resistant melanoma

Findings from a study carried out in mice suggest that an intermittent dosing strategy may be the answer to combating lethal tumor resistance to the BRAF inhibitor vemurafenib, in patients with late-stage BRAF-mutated melanoma.

14 Jan 2013

Melanomas that develop resistance to vemurafenib also become addicted to the drug

Researchers in California and Switzerland have discovered that melanomas that develop resistance to the anti-cancer drug vemurafenib (marketed as Zelboraf), also develop addiction to the drug, an observation that may have important implications for the lives of patients with late-stage disease.

11 Jan 2013

Moffitt Cancer Center initiates PV-10 Phase 1 study in melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, reports that the Moffitt Cancer Center has initiated a Phase 1 study to investigate potential immune biomarkers in both tumor tissue and peripheral blood after intralesional PV-10 injection of melanoma tumors.

9 Jan 2013

Overall cancer death rates continue to decline in the U.S.: Report

The Annual Report to the Nation on the Status of Cancer, 1975-2009, shows that overall cancer death rates continued to decline in the United States among both men and women, among all major racial and ethnic groups, and for all of the most common cancer sites, including lung, colon and rectum, female breast, and prostate.

9 Jan 2013

FDA approves use of iCAD's PowerLook AMP with Philips MicroDose Digital Mammography System

iCAD, Inc., an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced approval by the U.S. Food and Drug Administration for use of the company's next generation mammography computer-aided detection platform, PowerLook Advanced Mammography Platform, with Digital CAD for Philips' MicroDose Full-Field Digital Mammography System.

8 Jan 2013

Local conjunctival metastases ‘may be under-recognized’

Local conjunctival metastases may represent under-recognized lesions arising from the dissemination of primary conjunctival melanoma via local vessels, suggest findings published in the British Journal of Ophthalmology.

4 Jan 2013

Manipulating T cells with iPSC techniques could help develop effective immune therapies

The human body contains immune cells programmed to fight cancer and viral infections, but they often have short lifespans and are not numerous enough to overcome attacks by particularly aggressive malignancies or invasions.

4 Jan 2013

Scientists discover process by which mda-9/syntenin contributes to melanoma metastasis

After recently announcing success in eliminating melanoma metastasis in laboratory experiments, scientists at Virginia Commonwealth University Massey Cancer Center have made another important discovery in understanding the process by which the gene mda-9/syntenin contributes to metastasis in melanoma (the spread of skin cancer) and possibly a variety of other cancers.

4 Jan 2013

Melanoma patients may benefit from microRNA-26a replacement therapy

A University of Colorado Cancer Center study in this month's edition of the Journal of Investigative Dermatology describes a new target and potential treatment for melanoma, the most dangerous form of skin cancer. MicroRNA can decide which genes in a cell's DNA are expressed and which stay silent. Melanoma tends to lack microRNA-26a, which makes the gene SODD go silent.

21 Dec 2012

Investigators report non-coding miRNAs as appealing biomarkers for cancer malignancy

As many as 50 percent of all human protein-coding genes are regulated by microRNA (miRNA) molecules. While some miRNAs impact onset and progression of cancer, others can actually suppress the development of malignant tumors and are useful in cancer therapy. They can also serve as potential biomarkers for early cancer detection. In a new issue of Cancer Biomarkers, investigators report on non-coding miRNAs as appealing biomarkers for malignancy.

20 Dec 2012

MITF protein may help develop effective drug treatments for melanoma

Scientists at The University of Manchester have identified a protein that appears to hold the key to creating more effective drug treatments for melanoma, one of the deadliest cancers.

From The University of Manchester 19 Dec 2012

Researchers identify 125 genetic components in temozolomide-resistant, GBM-derived cell line

University of Pittsburgh Cancer Institute (UPCI) researchers have identified over 125 genetic components in a chemotherapy-resistant, brain tumor-derived cell line, which could offer new hope for drug treatment to destroy the cancer cells.

15 Dec 2012

Pairing statins with cyclin-dependent kinase inhibitors might effectively treat melanomas

A novel approach to identifying potential anticancer drug combinations revealed that pairing cholesterol-reducing drugs called statins with cyclin-dependent kinase inhibitors might provide an effective approach to treating intractable melanomas driven by mutations in the NRAS and KRAS gene.

14 Dec 2012

Melanoma News and Research

Latest Melanoma News and Research

Data from Provectus' PV-10 pre-clinical study on melanoma to be presented at AACR meeting

STA announces results from ABRAXANE plus gemcitabine phase III trial on pancreatic cancer

Incidence of melanoma continues to rise in both men and women: ACS

Report: Cancer death rates decline 20% from its peak in 1991

SF3B1 gene mutations in uveal melanoma linked to favorable features

Iris nevi have ‘low’ malignant potential

Aggressive surveillance questionable for eye melanoma recurrence

Intermittent therapy may be answer to treating drug-resistant melanoma

Melanomas that develop resistance to vemurafenib also become addicted to the drug

Moffitt Cancer Center initiates PV-10 Phase 1 study in melanoma

Overall cancer death rates continue to decline in the U.S.: Report

FDA approves use of iCAD's PowerLook AMP with Philips MicroDose Digital Mammography System

Local conjunctival metastases ‘may be under-recognized’

Manipulating T cells with iPSC techniques could help develop effective immune therapies

Scientists discover process by which mda-9/syntenin contributes to melanoma metastasis

Melanoma patients may benefit from microRNA-26a replacement therapy

Investigators report non-coding miRNAs as appealing biomarkers for cancer malignancy

MITF protein may help develop effective drug treatments for melanoma

Researchers identify 125 genetic components in temozolomide-resistant, GBM-derived cell line

Pairing statins with cyclin-dependent kinase inhibitors might effectively treat melanomas

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Melanoma News and Research

Latest Melanoma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in